PL2575881T3 - Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą - Google Patents

Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą

Info

Publication number
PL2575881T3
PL2575881T3 PL11728594T PL11728594T PL2575881T3 PL 2575881 T3 PL2575881 T3 PL 2575881T3 PL 11728594 T PL11728594 T PL 11728594T PL 11728594 T PL11728594 T PL 11728594T PL 2575881 T3 PL2575881 T3 PL 2575881T3
Authority
PL
Poland
Prior art keywords
neoangiogenesis
treatment
specific antibodies
eye disorders
disorders based
Prior art date
Application number
PL11728594T
Other languages
English (en)
Polish (pl)
Inventor
Philippe Le Bouteiller
Armand Bensussan
Original Assignee
Inserm - Institut National De La Santé Et De La Recherche Médicale
Elsalys Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm - Institut National De La Santé Et De La Recherche Médicale, Elsalys Biotech filed Critical Inserm - Institut National De La Santé Et De La Recherche Médicale
Publication of PL2575881T3 publication Critical patent/PL2575881T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11728594T 2010-05-28 2011-05-27 Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą PL2575881T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34927110P 2010-05-28 2010-05-28
EP11728594.0A EP2575881B1 (en) 2010-05-28 2011-05-27 Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
PCT/EP2011/058777 WO2011147984A1 (en) 2010-05-28 2011-05-27 Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis

Publications (1)

Publication Number Publication Date
PL2575881T3 true PL2575881T3 (pl) 2018-06-29

Family

ID=44276158

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11728594T PL2575881T3 (pl) 2010-05-28 2011-05-27 Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą

Country Status (11)

Country Link
US (2) US9045544B2 (enExample)
EP (1) EP2575881B1 (enExample)
JP (1) JP5990511B2 (enExample)
KR (1) KR101847572B1 (enExample)
CN (2) CN102892432A (enExample)
BR (1) BR112012030318A2 (enExample)
CA (1) CA2796312C (enExample)
DK (1) DK2575881T3 (enExample)
ES (1) ES2606627T3 (enExample)
PL (1) PL2575881T3 (enExample)
WO (1) WO2011147984A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561707B2 (en) * 2013-09-08 2020-02-18 Technion Research And Development Foundation Ltd. Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
EP3145532A4 (en) * 2014-05-02 2018-02-21 Mayo Foundation for Medical Education and Research Individualized treatment of eye disease
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018077926A1 (en) * 2016-10-25 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal antibodies binding to the cd160 transmembrane isoform
FR3061716B1 (fr) 2017-01-06 2019-05-17 Elsalys Biotech Nouveaux composes ciblant le cd160 humain
EP3675889A4 (en) * 2017-08-31 2021-05-12 Singapore Health Services PTE Ltd ANGIO -3 FOR THE TREATMENT OF ANGIOGENIC RETINAL DISEASES
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230073132A1 (en) * 2019-12-31 2023-03-09 Medstar Health, Inc. Anti-cd 160 binding molecules for treating diseases
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
JP2025534206A (ja) 2022-09-15 2025-10-15 アビディキュア アイピー ビー．ブイ． Ｎｋ細胞を刺激するための多重特異性抗原結合タンパク質及びその使用
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
JP3312357B2 (ja) 1992-12-11 2002-08-05 ザ ダウ ケミカル カンパニー 多価の一本鎖抗体
AU5253898A (en) 1996-11-12 1998-06-03 Dana-Farber Cancer Institute Recombinant by55 and nucleic acids encoding same
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
FR2794977B1 (fr) * 1999-06-18 2003-10-31 Commissariat Energie Atomique Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
EP1626059A1 (en) * 2004-08-09 2006-02-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2
US20090098139A1 (en) * 2006-01-30 2009-04-16 Barrett Katz Combination therapy for the treatment of neovascular disorders
AR062239A1 (es) 2007-08-07 2008-10-22 Civil De Estudios Superiores A Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal

Also Published As

Publication number Publication date
JP2013528607A (ja) 2013-07-11
BR112012030318A2 (pt) 2017-06-20
US10208124B2 (en) 2019-02-19
ES2606627T8 (es) 2017-06-09
CA2796312C (en) 2020-11-03
KR20130086548A (ko) 2013-08-02
EP2575881B1 (en) 2016-09-14
CN102892432A (zh) 2013-01-23
CA2796312A1 (en) 2011-12-01
US20130122006A1 (en) 2013-05-16
DK2575881T3 (en) 2017-01-09
US20150344572A1 (en) 2015-12-03
CN107648605A (zh) 2018-02-02
JP5990511B2 (ja) 2016-09-14
EP2575881A1 (en) 2013-04-10
ES2606627T3 (es) 2017-03-24
KR101847572B1 (ko) 2018-05-24
US9045544B2 (en) 2015-06-02
WO2011147984A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
PL2575881T3 (pl) Przeciwciała swoiste wobec CD160 do leczenia zaburzeń oczu związanych z angiogenezą
PT2785706T (pt) 4-fenil-piridinas substituídas para o tratamento de doenças relacionadas com o recetor de nk-1
IL229254A0 (en) Therapeutic antibodies
HUE047994T2 (hu) Bardoxolon-metil elhízás kezelésére
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
WO2011163452A8 (en) Treating surface of the eye disorders
IL232334A0 (en) Modulators of the G protein-coupled mas receptor and the treatment of related disorders
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
AP2013006985A0 (en) Fused dihydrofurans as GPR119 modulators for the treatment of diabetes, obesity and related disorders
IL230960A0 (en) A device for the treatment of eye disease
IL223290A (en) Anti-1α-il antibodies for the treatment of arthritis
IL227782A0 (en) Crystal forms and processes for the preparation of cannabinoid receptor modulators
IL230959A0 (en) A device for the treatment of eye disease
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
ZA201302639B (en) Antibodies for the treatment of hiv
GB201006166D0 (en) Compounds for the treatment of metabolic disorders
IL228973A0 (en) Oxymetazoline for the treatment of anorectal disorders
ZA201308992B (en) Therapeutic antibodies
GB201004744D0 (en) Compounds for the treatment of metabolic disorders
GB201006164D0 (en) Compounds for the treatment of metabolic disorders
GB201019482D0 (en) Compounds for the treatment of metabolic disorders
GB201006163D0 (en) Compounds for the treatment of metabolic disorders
GB201004742D0 (en) Compounds for the treatment of metabolic disorders
GB201004741D0 (en) Compounds for the treatment of metabolic disorders
GB201004740D0 (en) Compounds for the treatment of metabolic disorders